Biomedical R&D company
CSPC, founded in June, 1992 and headquartered in Shijiazhuang, is a biopharmaceutical developer. The founder is Cai Dongchen. Listed on the HKEX on June 21, 1994, the company's major shareholders are Massive Top. Limited. Rivals that have direct and indirect competition with CSPC include 111 Group, JD health, Glaxo Smith Kline, Pfizer, etc.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
ResearchConsumer Staples, Healthcare, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Immunotherapy in China: A Rising Star in the Field of Cancer Treatment
Immunotherapy is emerging as a powerful weapon in fighting cancer by restarting and maintaining the cancer-immunity cycle to identify, control and eliminate tumor cells rather than killing them directly.
Nov 24, 2022 06:29 PM
Challenges and Opportunities Possessed by Digital Therapeutics Industry
Following the digital therapeutics series report, this article is centered on the challenges and opportunities faced by the digital therapeutics industry and aims to provide insights on the two above aspects.
Nov 23, 2022 03:23 PM